All In Biotech

Drug Trial Radar · NCT03895112

MPN-RC 118 AVID200 in Myelofibrosis

Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118)

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Feb 15, 2019

Primary completion

May 16, 2022

Study completion May 16, 2022

Sponsor

Lead sponsor
John MascarenhasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Formation Biologics; National Cancer Institute (NCI); Myeloproliferative Neoplasm Research Consortium (MPN-RC)
First posted
Mar 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. AVID200 is a drug that targets TGF-β1 and TGF-β3. The study team hypothesizes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. Patients must have intermediate-2 or higher primary myelofibrosis (PMF), post-essential thrombocythemia or polycythemia-vera related MF (Post ET/PV MF). This study will enroll up to 24 patients. AVID200 is delivered by IV infusion on day 1 of each 3 week cycle.

Conditions

  • Primary Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post ET MF
  • Post PV MF

Interventions

  • AVID200Drug

    dose cohorts of 21-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximally tolerated dose (MTD) of AVID200Time frame: After 6 cycles (Each cycle is 21 days)
  2. Number of patients with response eligibility for Phase 1bTime frame: After 6 cycles

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icahn School of Medicine at Mount Sinai

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.